Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the

Global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C

Citizens analyst Silvan Turkcan reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperf

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the disco

 IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the disc

Collaboration to to evaluate the efficacy and safety of IDE892, its investigational, potential best-

Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and

Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the ana

IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative

IDEAYA Presentations:2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform

Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and

IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS

Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and

U.S. stock futures higher, Nasdaq up 200 points. Mission Produce (NASDAQ: AVO) shares down on weak e

GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) today announced that it intends to offer and sell up to $300.

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential b

Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and

Key Findings from OptimUM-02Primary endpoint (Phase 2 portion): progression free survival by BICRThe

Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.11) per share which missed the ana

- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today annou

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Neutral a

Wells Fargo analyst Eva Fortea Verdejo maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Overweig

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform

Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and

Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro

IDEAYA shares rise after darovasertib trial shows progression-free survival benefit in uveal melanom

IMA: 41% | ImageneBio Raises $30M Via Private Institutional Placement To Fund Hair Loss And Skin Dis

Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR,

Editor’s note: The future prices of benchmark tracking ETFs and pre-market prices of stocks have bee

IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plan

U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Wednesday. Here are

  During Thursday, 849 stocks hit new 52-week lows.

    On Monday, 466 companies hit new 52-week lows.